Cablivi

Caplacizumab-Yhdp

8.1 High risk

Cablivi & Product use in unapproved indication

13.2%

of users reported Product use in unapproved indication

70.0%

also reported Severe reaction

82.0%

are women

Most common medical consequences

Severe reaction
70.0%
Hospitalization
20.0%
Death
10.0%

Have you experienced any negative side effects from this medication?

Cablivi: general information

Most common side effects (19)

Most commonly affected ages

10 - 19 years
3.9%
20 - 29 years
11.4%
30 - 39 years
21.7%
40 - 49 years
20.8%
50 - 59 years
29.7%
60 - 69 years
12.5%
On this page
Cablivi & Product use in unapproved indication
Cablivi: general information